Metronidazole (Flagyl, and now the veterinary brand Ayradia) is one of the most commonly dispensed drugs in companion-animal medicine. It is a nitroimidazole with two jobs: it kills anaerobic bacteria, and it kills protozoa — most notably Giardia. That double coverage is why a veterinarian reaches for it when a dog or cat has diarrhea that could be parasitic, could involve anaerobic overgrowth, or is part of inflammatory bowel disease.

There is one fact about this drug that most pet-information pages still get wrong. Many still state flatly that "metronidazole is not FDA-approved for dogs." That was true for decades. It is no longer fully true. In October 2023 the FDA approved Ayradia (metronidazole oral suspension, NADA 141-572, sponsored by Virbac) for the treatment of Giardia duodenalis infection in dogs — the first FDA-approved animal drug for that parasite. What remains off-label is the older generic tablet form (Flagyl) and essentially every use in cats.

This article covers what metronidazole treats, the corrected FDA picture, the dose context a veterinarian works from, the neurological-toxicity risk that is the single most important safety issue for this drug, the diazepam rescue protocol, and an honest look at the adverse-event data. It is the drug-specific companion to the site's Giardia in dogs and acute diarrhea in dogs workups.

Quick answer

Metronidazole treats anaerobic infections, Giardia, and gastrointestinal inflammation in dogs and cats. Since October 11, 2023, the brand Ayradia oral suspension is FDA-approved for canine giardiasis at 25 mg/kg by mouth twice daily for 5 days; generic tablet metronidazole (Flagyl) is not FDA-approved for any animal and remains an extra-label (off-label) prescription written under veterinarian judgment. The key safety risk is cumulative-dose neurotoxicity — cerebellar and vestibular signs (ataxia, nystagmus, head tilt, tremor, and sometimes seizures) that appear most often above roughly 60 mg/kg/day or after prolonged courses, and that have been reported from as low as 26 mg/kg/day. Diazepam shortens recovery dramatically when toxicity occurs, from about 11 days with supportive care alone down to roughly 39 hours. Metronidazole is prohibited in food-producing animals in both the United States and the European Union.

What metronidazole treats (and what it does not cover)

Metronidazole's spectrum is narrow but specific. After it enters a susceptible organism, it is reduced inside anaerobic (or protozoal) cells into compounds that damage DNA and other cellular structures. Oxygenated, aerobic tissues are largely spared — which is what makes it selective for the organisms it targets.

The clinical uses a veterinarian is weighing include:

• Giardia duodenalis infection in dogs — the only FDA-approved veterinary indication, for which Ayradia oral suspension is labeled.
• Anaerobic bacterial infections — periodontal and oral-cavity infections, abscesses, deep pyodermas, and infections of the gut, liver, or urogenital tract where anaerobes such as Bacteroides, Clostridium, and Fusobacterium predominate.
• Certain diarrheal conditions — including Clostridium perfringens-associated diarrhea and, in some protocols, inflammatory bowel disease (IBD), where it is used for its immunomodulatory and antimicrobial effects.
• Selected protozoal infections beyond Giardia — historically including Trichomonas, although the preferred treatment for feline T. foetus (the cause of chronic large-bowel diarrhea in cats) is now non-metronidazole therapy.

What metronidazole does not cover is equally important. It has no meaningful activity against most aerobic bacteria, so a mixed infection — for example a bite wound with both aerobic and anaerobic organisms — typically needs a second drug. This is the logic behind pairing it with amoxicillin-clavulanate; see the site's clavamox comparison for how those spectra complement each other. It is also not an antifungal, not an antiviral, and not a parasite killer for worms (it will not touch hookworms, roundworms, or whipworms — those need an anthelmintic such as fenbendazole).

Is metronidazole FDA-approved for dogs, or is it off-label?

This is the question the existing search results answer badly, because the answer changed in 2023 and most pages were not updated. There are now two distinct approval situations, and conflating them is the error to avoid.

Ayradia (metronidazole oral suspension, 125 mg/mL) is FDA-approved. The FDA's Center for Veterinary Medicine approved it on October 11, 2023, under NADA 141-572, sponsored by Virbac AH, Inc. The labeled indication is the treatment of Giardia duodenalis infection in dogs, at a dose of 25 mg of metronidazole per kilogram of body weight given orally twice daily for 5 consecutive days. The FDA specifically noted that Ayradia is "the first FDA-approved animal drug for treating Giardia duodenalis infections," and the approval is recorded in the Code of Federal Regulations at 21 CFR 520.1425. Federal law restricts the drug to use by or on the order of a licensed veterinarian.

Generic tablet metronidazole (Flagyl and generics) is not FDA-approved for any animal species in the United States. When a veterinarian dispenses the tablet form for a dog or cat — or uses any metronidazole product for a cat — that is an extra-label (off-label) prescription made under the Animal Medicinal Drug Use Clarification Act (AMDUCA). The professional standard for extra-label use is that the veterinarian has determined, on the basis of available evidence and the individual patient, that the benefit outweighs the limitations. So the precise statement is: metronidazole the molecule now has one approved veterinary product (Ayradia, for canine giardiasis); all other metronidazole use in animals remains extra-label.

The Ayradia field studies are worth knowing about because they are the cleanest canine safety data we have. In the laboratory dose-characterization study, dogs received 12.5, 25, or 50 mg/kg twice daily; cyst excretion was suppressed far more at 25 and 50 mg/kg than at 12.5 mg/kg, which is why 25 mg/kg twice daily was selected. The most common adverse events in treated dogs were vomiting and diarrhea, which resolved without treatment, and neurological signs were not observed in the field study at the labeled dose. Virbac's prescribing information notes that neurologic effects have been associated with use at high doses and to use the drug with caution in dogs with hepatic dysfunction; safe use in breeding, pregnant, or lactating animals has not been evaluated.

How metronidazole works

Metronidazole is taken up by anaerobic and protozoal cells and reduced by ferredoxin-linked enzymes into short-lived cytotoxic intermediates. These intermediates bind DNA, disrupt the helical structure, and inhibit nucleic-acid synthesis, leading to cell death. Aerobic mammalian tissues and aerobic bacteria lack the low-redox-potential transport systems needed to reduce the drug in quantity, so they are comparatively spared. This selective activation is why metronidazole can hit anaerobes and protozoa hard while generally leaving the host and aerobic flora alone — though, as the next sections explain, it is not free of central-nervous-system effects at higher exposure.

Dose context — what the label says, and why your veterinarian personalizes it

No article can or should hand you a universal dose, because the right number depends on the species, the indication, the formulation, body weight, liver function, and other medications. What is useful is to know the reference points a veterinarian is working from so the prescription you receive makes sense.

• Ayradia oral suspension (FDA label): 25 mg/kg by mouth twice daily for 5 consecutive days, for canine giardiasis. This is the one approved, labeled canine regimen.
• Generic tablet (extralabel) dose ranges in the veterinary literature commonly fall in the roughly 10–25 mg/kg range given every 12 to 24 hours, with anaerobic-infection protocols sometimes using higher total daily doses for limited durations. The exact regimen, the duration, and the upper limit are decisions your veterinarian makes for the individual patient.
• Cats are often dosed at the lower end of published ranges, and because plain metronidazole tablets are intensely bitter, veterinarians and compounding pharmacies frequently use metronidazole benzoate (a palatable ester) for cats. Metronidazole benzoate appears on the FDA's list of bulk drug substances considered for compounding office stock for non-food-producing animals.

Two practical cautions follow from the dosing picture. First, because the tablet is bitter, hiding it well or using a compounded palatable form improves adherence — and adherence matters here, since under-dosing an infection invites resistance and treatment failure. Second, the published dose ranges have an upper boundary precisely because of neurotoxicity, which is the subject of the next section.

What are the warning signs of metronidazole neurotoxicity?

The single most important safety issue with metronidazole is central nervous system toxicity, and the reason it matters is that it is common enough to be a recognized syndrome and reversible when caught. The mechanism is not fully worked out; proposed explanations include inhibition of neuronal protein synthesis through RNA binding and thiamine antagonism. Pathology studies in affected dogs have shown axonal swelling in the vestibulocerebellar pathways and brainstem leukomalacia — that is, damage concentrated in the cerebellum and the central vestibular system, which is exactly what the clinical signs reflect.

The signs are a recognizable cluster:

• Ataxia — a wobbly, drunken, uncoordinated gait, often most visible in the hind limbs.
• Nystagmus — involuntary flicking or darting eye movements.
• Head tilt — the head held rotated to one side.
• Intention tremor and muscle spasms.
• Hypermetria (an over-reaching, high-stepping gait) and, in severe cases, recumbency (unable to stand), opisthotonus, and seizures.

A dog showing this cluster while on metronidazole — especially a dog that has been on it for more than a week or at a higher daily dose — should be seen promptly. The first step is stop the drug, which your veterinarian will direct.

Toxicity is overwhelmingly cumulative-dose and duration related. Most affected dogs have received weeks to months of therapy, but it has been documented after shorter courses and at lower daily doses than the classic thresholds. The practical reference points from the peer-reviewed and pharmacovigilance literature are:

• The Evans et al. (2003) case series of 21 dogs — the foundational study for treatment — reported average exposures of roughly 60 mg/kg/day for about 45 days in the diazepam-treated group and a similar daily dose for a somewhat shorter period in the untreated group.
• French national pharmacovigilance data (ANSES VigilAnses, reviewing 124 reports from 2001–2019, 99 in dogs) documented neurotoxicity at doses as low as 26 mg/kg/day, below the older thresholds — which is why cautious authors recommend caution above 40 mg/kg/day for any duration and vigilance above 60 mg/kg/day.
• A UK case series (Tauro et al., 2018) reported 26 dogs with daily doses ranging from 26 to 112 mg/kg/day (average about 42), with onset after about 10 days in the large majority.

The honest summary: there is no bright line below which toxicity is impossible, but the risk climbs steeply with higher daily doses and longer durations, and prolonged courses for chronic conditions (such as IBD) are the setting in which it most often appears.

The diazepam rescue: why recovery is measured in days, not weeks

Here is the part most pet pages bury. For decades, the only treatment for metronidazole toxicosis was to stop the drug and give supportive care, and recovery took one to two weeks. The Evans et al. (2003) retrospective study reshaped how the condition is treated by showing that diazepam (Valium) dramatically shortens recovery.

The protocol in that study was a single intravenous bolus of diazepam (average 0.43 mg/kg) followed by diazepam by mouth every 8 hours for 3 days (average oral dose 0.43 mg/kg). The results:

• Response time (resolution of the debilitating signs): about 13 hours with diazepam versus about 4 days with supportive care alone.
• Recovery time (resolution of all residual signs): about 39 hours with diazepam versus about 11 days with supportive care alone.

The proposed mechanism is that diazepam competes with metronidazole at the benzodiazepine site of the GABA receptor in the cerebellar and vestibular systems, displacing the drug and restoring inhibitory tone. Because metronidazole's plasma half-life is short, once displaced it is cleared, and the clinical improvement tracks that clearance. This is why a veterinarian who suspects metronidazole toxicosis will often prescribe a short diazepam course rather than simply waiting it out.

Two species caveats on diazepam. Cats should not receive oral diazepam casually, because oral diazepam has been associated with idiosyncratic, potentially fatal liver injury in cats — a cat with suspected metronidazole toxicity needs a veterinarian's individualized decision rather than an assumption that the canine protocol transfers directly. And diazepam itself is a controlled substance with sedation and ataxia as effects, so the rescue is a clinical decision, not a home remedy.

The openFDA adverse-event profile (and how to read it)

VetMedGuide maintains a deduplicated adverse-event analysis for the most commonly dispensed companion-animal drugs, drawn from the FDA's openFDA animal adverse-event dataset (the events feed, not the reactions feed). For metronidazole, the deduplicated count — collapsing to one record per unique adverse-event report identifier — is 3,492 reports as of the June 2026 dataset export.

The breakdown of those reports:

• Species: Dog 2,903; Cat 372; species not specified 196; with small numbers in horses, ferrets, a chinchilla, and a rabbit (and a handful of human exposures). It is overwhelmingly a companion-animal, dog-dominated signal.
• Outcomes: Recovered/normal in 788; ongoing in 1,175; outcome unknown in 633; died in 278; euthanized in 371; recovered with sequela in 35.
• Most frequently reported reaction terms: diarrhea (951), vomiting (882), lethargy / central-nervous-system depression (776 combined), anorexia (398), elevated liver enzymes including ALT (341), weight loss (308), and bloody diarrhea (285).
• Neurotoxicity-spectrum terms — the cluster this article cares about most — were clearly visible: ataxia (179), seizure terms (158, of which "seizure" not otherwise specified was the largest component), tremor (81), nystagmus (47), and head tilt (39).
• About 1,753 of the reports (roughly half) carried a "serious" flag.

Three things must be said plainly about these numbers. First, they are passive-surveillance reports, not incidence rates and not proof of causality — a report filed after a dog took metronidazole does not mean metronidazole caused the outcome, because sick dogs are often on multiple drugs and have serious underlying disease. Second, many of the gastrointestinal and death/euthanasia reports reflect the severity of the underlying illness being treated (severe colitis, IBD, sepsis) as much as any drug effect. Third, the consistency of the neurotoxicity cluster across the openFDA data, the published case series, and the FDA's own Ayradia label language ("neurologic effects have been associated with use at high doses") is what makes cumulative-dose neurotoxicity the defensible, take-home safety message — not the raw report counts.

This metronidazole profile is part of the site's broader openFDA anti-infective adverse-event analysis, which explains the dataset, the deduplication method, and the passive-surveillance caveats in more detail.

How does metronidazole use differ between dogs, cats, and food animals?

The species lines on this drug are sharp, and getting them wrong has real consequences.

Dogs are the species with an actual FDA-approved product (Ayradia) and the deepest published safety data, including the diazepam rescue literature. Canine use — for giardiasis, anaerobic infections, and selected diarrheal conditions — is well established.

Cats are treated extra-label. Two specifics matter. The bitter taste of plain tablets makes adherence difficult, which is the practical reason metronidazole benzoate (the palatable ester) is favored. And the neurotoxicity signs in cats can include forebrain signs (disorientation, behavior change, seizures) in addition to the vestibular-cerebellar signs seen in dogs, so the presenting picture may look different. As noted above, the oral diazepam rescue used in dogs does not transfer cleanly to cats because of feline hepatic risk.

Food-producing animals are the hard line. Metronidazole and the other nitroimidazoles are prohibited in food-producing animals. In the European Union, Commission Regulation (EC) No 37/2010 lists metronidazole in the prohibited-substances table (Table 2) alongside dimetridazole, ronidazole, the nitrofurans, and chloramphenicol — substances for which no maximum residue limit can be established because no safe residue level has been demonstrated. In the United States, AMDUCA specifically prohibits the extra-label use of certain drugs — including the nitroimidazoles — in food-producing animals. The rationale is a combination of carcinogenicity concern from residues and the lack of an established safe withdrawal threshold. The practical point for a companion-animal owner is that this prohibition is about the human food chain, not about your dog or cat; it does not make metronidazole dangerous for a pet, but it is the reason a veterinarian will never prescribe it for a production animal.

Exotic companion animals sit in between. Metronidazole is one of the relatively safer options for anaerobic infections in rabbits and rodents, but these species are exquisitely sensitive to antibiotic-induced dysbiosis, so any use is a specialist decision — see the site's rabbit antibiotic safety guide for why drug choice in exotic species is never a casual transfer from dog and cat medicine.

Contraindications, interactions, and monitoring

Metronidazole is not appropriate for every patient. The situations a veterinarian is screening for include:

• Pregnancy and lactation — safe use in pregnant or lactating bitches has not been established, and the drug crosses the placenta. Early pregnancy and breeding animals are treated with caution.
• Young animals — particularly very young puppies and kittens, where clearance and dosing precision are concerns.
• Liver disease — metronidazole is hepatically metabolized, and in liver dysfunction the drug accumulates, both prolonging the half-life and raising the neurotoxicity risk. Dose reduction and longer dosing intervals are typical, and the Ayradia label specifically cautions about hepatic dysfunction.
• Central nervous system disease or a history of seizures — a patient already neurologically vulnerable gets extra scrutiny because the toxicity presents neurologically.
• Warfarin and related anticoagulants — metronidazole can potentiate the anticoagulant effect, a relevant interaction in the rare companion animal on such therapy.
• Alcohol-containing formulations or co-administration with alcohol — a disulfiram-like reaction is possible, which is more relevant to compounded and human formulations than to standard veterinary dispensing.

Monitoring on a prolonged course typically includes watching for the early neurological signs above (a wobbly gait or odd eye movement is reason to call before the next dose), and for extended use, periodic liver enzymes. The elevated-ALT signal in the openFDA data is a reminder that hepatic effects are part of the profile, particularly with longer durations.

When metronidazole is not the right fit — and what comes next

Metronidazole is overused in first-opinion practice, and the honest article acknowledges that. A double-blind, placebo-controlled trial of metronidazole for acute nonspecific diarrhea in dogs (published in the Journal of Veterinary Internal Medicine) found that it shortened the course only modestly compared with placebo — and because most acute, uncomplicated canine diarrhea is self-limiting, the marginal benefit has to be weighed against the microbiome disruption that any antibiotic causes. This is the antimicrobial-stewardship argument against reaching for metronidazole reflexively for every loose stool; the site's acute diarrhea in dogs workup lays out when supportive care and diet are enough and when an antimicrobial is actually indicated.

Cases where metronidazole is genuinely the wrong choice include uncomplicated viral or dietary diarrhea, parasitic disease caused by organisms it does not cover (most worms), and any situation where a culture-and-sensitivity result points to a more targeted agent. For confirmed giardiasis, fenbendazole is an effective alternative and is the comparator used in the Ayradia field program. For anaerobic coverage where oral medication is difficult, the injectable form is available for in-hospital use.

The decision framework, simplified: use metronidazole when there is a specific reason to suspect Giardia or anaerobic involvement, use the shortest effective course, watch for the neurological cluster, and never use it in a food animal.

Frequently asked questions

Can metronidazole be given long-term for inflammatory bowel disease in dogs?

Metronidazole has been used as part of some IBD protocols for its antimicrobial and immunomodulatory effects, but long-term daily use is exactly the setting in which cumulative-dose neurotoxicity appears, and modern IBD management generally favors limiting antibiotic courses and relying on diet, corticosteroids, or other immunomodulators for long-term control. If your dog is on metronidazole for IBD, ask your veterinarian about the planned duration, the monitoring schedule, and what the longer-term maintenance plan is — open-ended daily metronidazole is no longer the default.

What happens if a dog gets too much metronidazole, and how fast do they recover?

The signature problem is neurotoxicity — the wobbly gait, abnormal eye movements, head tilt, and tremor described above — and it is cumulative-dose related. Recovery is measured in days to about two weeks with supportive care alone, but a short course of diazepam, given under veterinary direction, has been shown to cut recovery to roughly a day and a half. If you see those signs, stop the drug and call your veterinarian immediately; do not "wait and see" through a worsening neurological picture.

Why was I told metronidazole is not FDA-approved when Ayradia exists?

Because the statement is partly out of date. Ayradia oral suspension was approved in October 2023 for canine giardiasis, so for that specific product and indication metronidazole now is FDA-approved. What is still not approved is generic tablet metronidazole (Flagyl) for any animal species and any use in cats — those remain extra-label. Many older resources have not caught up to the 2023 approval.

Is metronidazole safe for cats?

It is used in cats, extra-label, and is generally tolerated when dosed appropriately — often as the palatable benzoate ester because plain tablets are too bitter. The two feline-specific cautions are that toxicity can present with forebrain (behavioral, seizure) signs as well as vestibular signs, and that oral diazepam — the canine rescue drug — carries a serious liver-injury risk in cats and is not a simple transfer.

Sources

• FDA Center for Veterinary Medicine. "FDA Approves First Treatment for Giardia duodenalis in Any Animal Species." October 11, 2023. https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-treatment-giardia-duodenalis-any-animal-species
• FDA. Corrected Freedom of Information Summary, NADA 141-572, AYRADIA (metronidazole oral suspension), approved October 11, 2023. https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14645
• Code of Federal Regulations, 21 CFR 520.1425, Metronidazole (approval action, NADA 141-572, Virbac AH, Inc.). Federal Register, February 27, 2024. https://www.federalregister.gov/documents/2024/02/27/2024-03765/new-animal-drugs-approval-of-new-animal-drug-applications-withdrawal-of-approval-of-new-animal-drug
• DailyMed. AYRADIA (metronidazole) oral solution, label and prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc79a63f-e3a3-4781-9c8f-7a128310fa6c
• Virbac. AYRADIA (metronidazole oral suspension) for dogs — prescribing information and Important Safety Information. https://vet-us.virbac.com/home/products/antibiotics/ayradia-oral-suspension.html
• Evans J, Levesque D, Knowles K, et al. "Diazepam as a treatment for metronidazole toxicosis in dogs: a retrospective study of 21 cases." Journal of Veterinary Internal Medicine, 2003;17(3):304–310. https://pubmed.ncbi.nlm.nih.gov/12774970
• Tauro A, Beltran E, Cherubini GB, et al. "Metronidazole-induced neurotoxicity in 26 dogs." Australian Veterinary Journal, 2018;96:495–501. https://onlinelibrary.wiley.com/journal/17517321
• ANSES. "Neurotoxicity of metronidazole, an antibiotic and antiparasitic." VigilAnses N°13, March 2021. https://vigilanses.anses.fr/sites/default/files/VigilAnsesN13_March%202021_Metronidazole.pdf
• Detroit E, Beck A. "Metronidazole for the treatment of acute diarrhea in dogs: a randomized, double-blind, placebo-controlled trial." Journal of Veterinary Internal Medicine / PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC6979100
• European Commission. Commission Regulation (EU) No 37/2010 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (metronidazole, Table 2 — prohibited substances). Official Journal L 15, 2010. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:015:0001:0072:EN:PDF
• Merck Veterinary Manual. "Nitroimidazoles Use in Animals." https://www.merckvetmanual.com/pharmacology/antibacterial-agents/nitroimidazoles-use-in-animals
• FDA. "List of Bulk Drug Substances for Compounding Office Stock Drugs for Use in Non-Food-Producing Animals" (metronidazole benzoate). https://www.fda.gov/animal-veterinary/animal-drug-compounding/list-bulk-drug-substances-compounding-office-stock-drugs-use-nonfood-producing-animals
• VetMedGuide openFDA adverse-event analysis (animal adverse-event events dataset, June 2026 export; deduplicated by unique report identifier; passive-surveillance counts, not incidence). Method described in the site's openFDA anti-infective adverse-event analysis.